| Name | Title | Contact Details |
|---|
Excel Imaging Inc is a Iowa Park, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aaptiv is a mobile fitness product that is reinventing the way people workout, with audio classes that combine the motivation of a professional trainer with an incredible playlist. From truly fun treadmill workouts to effective elliptical classes, and interval routines that burn major calories, start enjoying your cardio with Aaptiv. Our team is dedicated to the belief that high-quality fitness instruction should not be a privilege for a few, but a right for all. We don`t think of fitness as an end goal, but rather a tool that fuels a richer, more successful life. We are looking for team members who are excited and eager to support our members by building the world`s best audio fitness product!
Panhandle Eye Group is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Amarillo, TX. To find more information about Panhandle Eye Group, please visit www.paneye.com
We connect world class science to consumer health. We use science and math to enable average consumers to understand their health risk relative to their peers (age & gender) based on their behaviors. We enable organizations to develop affinity with their members, employees, patients and customers by facilitating consumer-driven, personalized user experiences. We do the heavy lifting and provide you with the data. We facilitate a permanent relationship with consumers, providing value as an entry point to preventative self-directed healthcare.
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.